Joseph Falsone, MD
Cardiovascular Disease · Raleigh, NCNPI 1952309494
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,184 of the $9,386 with a category attached, or 65.9%. 28 manufacturers reported payments, led by Amgen at 33.7% of the total. Reporting peaked in 2019 at $5,659 and has fallen 94.6% since, to $304 in 2025.
Across 130 payments — averaging $72.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Biotronik Inc.$3K
- E.r. Squibb & Sons, L.L.C.$496
- Boston Scientific$421
- Elutia, Inc.$401
- Medtronic$314
- plus $2K from 22 others
Across 6 payments — averaging $7716.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Elutia, Inc.$46K
What the payments were for
- Speaking & faculty fees$2,60028%
- Grants$1001%
- Travel & lodging$4725%
- Food & beverage$6,18466%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $3,165 |
| Biotronik Inc. | 25 | $2,628 |
| E.r. Squibb & Sons, L.L.C. | 14 | $496 |
| Boston Scientific | 4 | $421 |
| Elutia, Inc. | 11 | $401 |
| Medtronic | 4 | $314 |
| Abbott | 6 | $267 |
| Amarin Pharma, Inc. | 8 | $248 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $234 |
| Irhythm Technologies, Inc. | 5 | $177 |
| Braemar Manufacturing, LLC | 1 | $164 |
| Cardiva Medical, Inc. | 1 | $146 |
| Pfizer | 2 | $133 |
| Boehringer Ingelheim | 7 | $116 |
| Johnson & Johnson | 4 | $73 |
| Novartis | 4 | $61 |
| Actelion Pharmaceuticals US, Inc. | 2 | $54 |
| AstraZeneca | 3 | $52 |
| Davol Inc. | 2 | $48 |
| GSK | 3 | $42 |
| Baxter Healthcare | 2 | $37 |
| Philips North America LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $16 |
| CMP Pharma, Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Abiomed | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$3,072
- BioMonitor$712
- Acticor$419
- Solia$419
- Rivacor$419
- Edora$419
- ECM Patch,Pouch$315
- Vascepa$215
- ONYX FRONTIER$184
- Cardiac Monitoring Suite$164
- Cardiva VASCADE 6/7F VCS$146
- GENERAL - THERAPIES$142
- Watchman$138
- CAMZYOS$132
- ELIQUIS$122
- GENERAL BRADY$119
- Allure Quadra RF CRT Pacemaker$111
How this compares
$9,386 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,135 | $1,027,434 |
| XareltoRivaroxaban | 104 | $127,102 |
| EntrestoSacubitril/Valsartan | 61 | $62,696 |
| Repatha SureclickEvolocumab | 41 | $33,823 |
| Praluent PenAlirocumab | 23 | $28,731 |
| Amiodarone Hcl | 501 | $14,799 |
| Metoprolol Succinate | 1,358 | $14,482 |
| Ranolazine ErRanolazine | 84 | $9,981 |
| JardianceEmpagliflozin | 12 | $9,276 |
| Hydralazine Hcl | 531 | $8,755 |
| Losartan Potassium | 910 | $8,198 |
| Flecainide Acetate | 292 | $7,925 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 268 | $5,018 |
| Atorvastatin Calcium | 441 | $4,658 |
| Torsemide | 258 | $3,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $133 | $1,027,4341,135 claims |
| Johnson & JohnsonXarelto | $73 | $127,102104 claims |
| NovartisEntresto | $61 | $62,69661 claims |
| Boehringer IngelheimJardiance | $116 | $9,27612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Raleigh
- Christopher KellyRaleigh$201K
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
- Adrian HernandezDurham$409K
- Sanjeev GulatiCharlotte$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.